Company profile: Locus Biosciences
1.1 - Company Overview
Company description
- Provider of CRISPR-engineered precision antibacterial therapies using bacteriophages. Portfolio includes LBP-EC01 for E. coli urinary tract infections; LBP-PA01 and LBP-SA01 targeting P. aeruginosa and S. aureus with Janssen; and LBP-KP01 for K. pneumoniae supported by CARB-X. Also offers robotic bacteriophage discovery and synthetic biology to engineer phage products.
Products and services
- LBP-KP01: A CRISPR-enhanced bacteriophage product targeting K. pneumoniae infections, with development supported by CARB-X
- LBP-PA01: A precision therapeutic architected to target P. aeruginosa infections, developed in partnership with Janssen Pharmaceuticals
- LBP-EC01: A CRISPR-enhanced bacteriophage therapy targeting E. coli bacteria for the treatment of urinary tract infections
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Locus Biosciences
4D Path
HQ: United States
Website
- Description: Provider of H&E biopsy/resection image analysis, including 4D Q-Plasia OncoReader Breast (software-as-a-medical-device) for diagnostic accuracy in breast cancer and 4D Q-Plasia OncoReader Pan-Cancer, a cloud platform identifying cancer type, molecular subtypes, grades, and molecular profiles. Also offers automated detection and prognostic evaluation from H&E whole slide images and biomarker profiling and stratification for precision oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Path company profile →
C2i Genomics
HQ: United States
Website
- Description: Provider of cloud-based cancer diagnostic services for pharmaceutical and diagnostic organizations, offering the C2-Intelligence Platform that leverages whole-genome sequencing and AI to detect minimal residual disease, low-input liquid biopsy, and services for MRD-guided adjuvant treatment, organ preservation decisions, treatment response monitoring, and early recurrence detection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C2i Genomics company profile →
Genelex
HQ: United States
Website
- Description: Provider of pharmacogenetic testing for precision medication management, backed by innovative analytics software, state-of-the-art laboratory facilities, and expert staff; a pioneer in DNA testing since 1987.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genelex company profile →
Spindiag
HQ: Germany
Website
- Description: Provider of an easy-to-use, compact, automated point-of-care PCR system for broad, fast, and affordable pathogen detection. The Rhonda player with Rhonda disks detects infectious agents—including SARS-CoV-2, Influenza A/B, RSV, and MRSA—with results in under one hour; the SARS-CoV-2 disk supports direct swab insertion. The Rhonda app displays results for mobile use, and test outcomes can be transferred directly into patient records.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spindiag company profile →
NAT Diagnostics
HQ: United States
Website
- Description: Provider of a molecular diagnostic platform for true point-of-care infectious disease testing in physician offices, clinics, pharmacies, and other sites where patients are seen by medical personnel, delivering highly accurate results to improve the diagnostic experience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NAT Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Locus Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Locus Biosciences
2.2 - Growth funds investing in similar companies to Locus Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Locus Biosciences
4.2 - Public trading comparable groups for Locus Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →